Results 111 to 120 of about 19,507 (228)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events

Clinical and Translational Science, 2022
John T. Sullivan
doaj   +1 more source

Postmarketing Surveillance [PDF]

, 2020
openaire   +1 more source

Pattern of sumatriptan use and overuse in general practice [PDF]

, 1996
Grobbee, D.E. (Diederick), Ottervanger, J.P. (Jan Paul), Stricker, B.H.Ch. (Bruno), Valkenburg, H.A. (Hans)   +3 more
core   +2 more sources

Incentivizing Postmarketing Pharmaceutical Product Safety Testing with Extension of Exclusivity Periods [PDF]

, 2008
Kushner, Leslie
core   +1 more source

Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System. [PDF]

JAAD Int
Alomary SA, Baker NJ, Ogunleye T, Taylor SC.   +3 more
europepmc   +1 more source

Premarket and postmarket real-world evidence studies supporting U.S. Food and Drug Administration regulatory decision-making, 2016-2024. [PDF]

Clin Trials
Li LY, Ramachandran R, Ross JS, Wallach JD.   +3 more
europepmc   +1 more source

Postmarketing Commitment [PDF]

, 2020
openaire   +1 more source

Current and Ongoing Clinical Studies. [PDF]

Muscle Nerve
Abrahao A, Zinman L, Apple S.
europepmc   +1 more source

Adverse events associated with use of immunoglobulin in pediatric patients reported to the US Food and Drug Administration Adverse Event Reporting System, 2001-2023. [PDF]

Pediatr Allergy Immunol
Wei S, Kim Y, Rubin MN, Ayyala SS, Welsh K.   +4 more
europepmc   +1 more source

Opportunities and Challenges of Using Big Data to Detect Drug-Drug Interaction Risk [PDF]

, 2019
Chasioti D., Institute of Medicine Committee on Data Standards for Patient Safety   +1 more
core   +1 more source